Connective Portfolio Management LLC Has $1.36 Million Stake in Natera, Inc. (NASDAQ:NTRA)

Connective Portfolio Management LLC lowered its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 4.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,600 shares of the medical research company’s stock after selling 400 shares during the quarter. Natera comprises approximately 2.0% of Connective Portfolio Management LLC’s investment portfolio, making the stock its 20th biggest position. Connective Portfolio Management LLC’s holdings in Natera were worth $1,361,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in NTRA. Chartwell Investment Partners LLC raised its position in shares of Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after buying an additional 11,362 shares in the last quarter. Cerity Partners LLC lifted its stake in Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after purchasing an additional 18,316 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Natera in the 3rd quarter valued at $385,000. Everence Capital Management Inc. bought a new position in shares of Natera in the 4th quarter valued at $573,000. Finally, Jag Capital Management LLC raised its holdings in shares of Natera by 8.8% during the 3rd quarter. Jag Capital Management LLC now owns 175,590 shares of the medical research company’s stock worth $22,291,000 after buying an additional 14,159 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Stock Up 2.8 %

Shares of NASDAQ:NTRA opened at $170.35 on Thursday. Natera, Inc. has a 1 year low of $59.80 and a 1 year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The business’s 50-day moving average is $162.75 and its 200-day moving average is $133.52.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue was up 63.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.95) earnings per share. On average, research analysts anticipate that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on NTRA shares. Robert W. Baird lifted their target price on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. upped their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. TD Cowen increased their price target on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Sanford C. Bernstein boosted their price objective on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus target price of $158.00.

Insiders Place Their Bets

In related news, Director Rowan E. Chapman sold 1,767 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $170.24, for a total value of $300,814.08. Following the transaction, the director now directly owns 6,202 shares in the company, valued at $1,055,828.48. This trade represents a 22.17 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 1,709 shares of the business’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $120.76, for a total transaction of $206,378.84. Following the sale, the chief executive officer now owns 194,615 shares of the company’s stock, valued at $23,501,707.40. This trade represents a 0.87 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 123,409 shares of company stock worth $20,045,631. 7.60% of the stock is currently owned by company insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.